MedTrace Logo

Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril

NCT03730116 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1909

Last updated 2021-01-13

Study results available
· View outcomes & findings →

Summary

Study objective - to assess the efficacy, tolerability and adherence of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice.

Type of the program: multicenter, observational, uncontrolled, open program. The program will involve 480 general practitioners (GPs) and cardiologists from the primary care facilities.Each doctor includes four patients. It is planned to include not less than 1920 patients in total.

Conditions

  • Arterial Hypertension
  • CHD - Coronary Heart Disease

Interventions

DRUG

bisoprolol/perindopril FDC

the first and only single-pill combination of beta-blocker and ACE inhibitor

Sponsors & Collaborators

  • Servier Russia

    lead INDUSTRY

Principal Investigators

  • Sergei Boytsov

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-14
Primary Completion
2019-10-24
Completion
2019-10-24

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03730116 on ClinicalTrials.gov